Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotec) filed a Next Day Disclosure Return on 11 May 2026, detailing its latest H-share repurchase and the status of its issued share capital.

Haohai Biotec’s share capital remains unchanged at 226.13 million ordinary shares, comprising 190.20 million A shares and 35.93 million H shares. No new shares were issued and no treasury shares were cancelled during the reporting period.

On 11 May 2026, the company bought back 43,700 H shares on the Stock Exchange of Hong Kong at prices between HKD22.72 and HKD22.86, spending HKD0.997 million. These shares are scheduled for cancellation.

Including this transaction, Haohai Biotec has 945,200 H shares repurchased but not yet cancelled from trades conducted between 23 March and 11 May 2026. Total repurchases under the mandate approved on 10 June 2025 stand at 3.55 million H shares, utilising 9.06 % of the 3.91 million-share limit.

Pursuant to Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares following the latest buyback, expiring on 10 June 2026.